Clinical trials: Pulmonary Artery Hypertension
Pulmonary Artery Hypertension
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure.
- Trial name
- NCT03979482
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension
Assessment of the prognostic value of the estimation of plasma volume or its variation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) after acute right heart…
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Acute Right Heart Failure
- Trial name
- NCT05861479
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Pulmonary Arterial Hypertension
RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
- Trial name
- RAMPHA (NCT05600218)
- Testing
- No intervention - Observational study
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Costa del Sol
Pre-capillary Pulmonary Hypertension
Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension
This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary…
- Trial name
- NCT07176260
- Testing
- Patients with pre-Capillary pulmonary hypertension
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Pulmonary Arterial Hypertension (PAH), Comorbidities
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
- Trial name
- COMMODITIES (NCT07245680)
- Testing
- Tadalafil, Ambrisentan
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Idiopathic Arterial Hypertension
Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of…
- Trial name
- NCT00551408
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Unidad de Investigacion Clinica en Medicina S.C.
Pulmonary Arterial Hypertension (PAH)
AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension is a rare and progressive condition that compromises pulmonary circulation and can lead to right ventricular failure.
- Trial name
- AIRDROP (NCT07457762)
- Testing
- The patients will receive guidance on inhaler use and adherence
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.
This pilot clinical trial analysis will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber supplementation vs.
- Trial name
- NCT07751120
- Testing
- MTT with antibiotic preconditioning + fiber supplementation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Pulmonary Arterial Hypertension
The Effect of Adding Exercise Training to Optimal Therapy in PAH
Exercise capacity (EC) is limited in pulmonary arterial hypertension (PAH) by impaired right ventricular (RV) function and inability to increase stroke volume (SV). Disease targeted therapy, increases EC by improving SV.
- Trial name
- NCT02961023
- Testing
- Exercise therapy
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- National Health Service, United Kingdom
Pulmonary Arterial Hypertension
Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)
Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and eventually to death.
- Trial name
- EVITA (NCT02845518)
- Testing
- Cardiac magnetic resonance imaging (cMRI)
- Where
- France
- Volunteers
- 169 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure, Pulmonary Arterial Hypertension
The CardioMEMS Vericiguat Heart Failure Trial
The ARETHA trial is a national (Danish), multicenter, randomized, placebo-controlled, double-blind, cross-over, no run-in phase, phase 4, investigator-initiated clinical trial investigating the effect of vericiguat on diastolic…
- Trial name
- ARETHA (NCT06671990)
- Testing
- Vericiguat
- Volunteers
- 17 people
- Sponsor
- Finn Gustafsson
Pulmonary Hypertension
Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure
A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.
- Trial name
- PADN-5 (NCT02220335)
- Testing
- Pulmonary arterial denervation, Standard treatment
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension, PAH
Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
The study is designed as a non-interventional, multicenter, prospective single-arm study to observe the therapy with REMODULIN (Treprostinil) applicated by an implantable pump in patients with pulmonary arterial hypertension…
- Trial name
- LPS-II (NCT04309838)
- Testing
- Treprostinil via implanted pump
- Where
- 8 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Medicine Greifswald
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension.
- Trial name
- NCT01451255
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension PAH
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk…
- Trial name
- NCT06477640
- Testing
- Exercise, Standard of Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Rochester
Pulmonary Arterial Hypertension, Heart Defects, Congenital
The Effects of the Otago Exercise Program
The objective of this experimental study is to conduct a comparative evaluation of the effects of a supervised Otago Exercise Program (OEP) functional exercise capacity, blood lactate levels, dyspnea, fatigue, peripheral muscle…
- Trial name
- NCT06172790
- Testing
- Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Hypertension
Novel Index (PIMR) in PAH
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and…
- Trial name
- NCT05812976
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension, Congenital Heart Disease
Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
SUMMARY Rationale: Pulmonary arterial hypertension (PAH) can be a rapidly progressive disorder and is associated with a high mortality rate, despite medical intervention.
- Trial name
- BICYCLE (NCT01827059)
- Testing
- Bosentan
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)